$11.5 Million Upfront with up to an Additional$11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with participation from new and existing healthcare focused institutional ...